title: Assessment of in vivo and in vitro genotoxicity of glibenclamide in eukaryotic cells.
abstract: Glibenclamide is an oral hypoglycemic drug commonly prescribed for the treatment of type 2 diabetes mellitus, whose anti-tumor activity has been recently described in several human cancer cells. The mutagenic potential of such an antidiabetic drug and its recombinogenic activity in eukaryotic cells were evaluated, the latter for the first time. The mutagenic potential of glibenclamide in therapeutically plasma (0.6 μM) and higher concentrations (10 μM, 100 μM, 240 μM and 480 μM) was assessed by the in vitro mammalian cell micronucleus test in human lymphocytes. Since the loss of heterozygosity arising from allelic recombination is an important biologically significant consequence of oxidative damage, the glibenclamide recombinogenic activity at 1 μM, 10 μM and 100 μM concentrations was evaluated by the in vivo homozygotization assay. Glibenclamide failed to alter the frequency of micronuclei between 0.6 μM and 480 μM concentrations and the cytokinesis block proliferation index between 0.6 μM and 240 μM concentrations. On the other hand, glibenclamide changed the cell-proliferation kinetics when used at 480 μM. In the homozygotization assay, the homozygotization indices for the analyzed markers were lower than 2.0 and demonstrated the lack of recombinogenic activity of glibenclamide. Data in the current study demonstrate that glibenclamide, in current experimental conditions, is devoid of significant genotoxic effects. This fact encourages further investigations on the use of this antidiabetic agent as a chemotherapeutic drug.
authors: Departamento de Biotecnologia, Genética e Biologia Celular, Laboratório de Genética de Microorganismos e Mutagênese, Universidade Estadual de Maringá, Maringá, Paraná, Brazil.
authors: Juliane Rocha
authors: JR
authors: de Sant'Anna
authors: Departamento de Biotecnologia, Genética e Biologia Celular, Laboratório de Biologia Celular e Secreção, Universidade Estadual de Maringá, Maringá, Paraná, Brazil.
authors: Claudinéia Conationi da Silva
authors: CC
authors: Franco
authors: Departamento de Biotecnologia, Genética e Biologia Celular, Laboratório de Biologia Celular e Secreção, Universidade Estadual de Maringá, Maringá, Paraná, Brazil.
authors: Paulo Cezar de Freitas
authors: PC
authors: Mathias
authors: Departamento de Biotecnologia, Genética e Biologia Celular, Laboratório de Genética de Microorganismos e Mutagênese, Universidade Estadual de Maringá, Maringá, Paraná, Brazil.
authors: Marialba Avezum Alves
authors: MA
authors: de Castro-Prado
mesh_terms: D000328:Adult; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005905:Glyburide / Q000633:toxicity*; D006801:Humans; D007004:Hypoglycemic Agents / Q000633:toxicity*; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D015162:Micronucleus Tests; D009153:Mutagens / Q000633:toxicity*; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D009153:Mutagens; D005905:Glyburide